Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OFATUMUMAB Cause Multiple organ dysfunction syndrome? 18 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 18 reports of Multiple organ dysfunction syndrome have been filed in association with OFATUMUMAB (ARZERRA). This represents 0.1% of all adverse event reports for OFATUMUMAB.

18
Reports of Multiple organ dysfunction syndrome with OFATUMUMAB
0.1%
of all OFATUMUMAB reports
17
Deaths
6
Hospitalizations

How Dangerous Is Multiple organ dysfunction syndrome From OFATUMUMAB?

Of the 18 reports, 17 (94.4%) resulted in death, 6 (33.3%) required hospitalization, and 3 (16.7%) were considered life-threatening.

Is Multiple organ dysfunction syndrome Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OFATUMUMAB. However, 18 reports have been filed with the FAERS database.

What Other Side Effects Does OFATUMUMAB Cause?

Fatigue (5,202) Headache (4,430) Pain (3,382) Chills (3,372) Pyrexia (3,370) Influenza like illness (2,727) Nausea (1,688) Multiple sclerosis relapse (1,525) Covid-19 (1,435) Asthenia (1,393)

What Other Drugs Cause Multiple organ dysfunction syndrome?

TACROLIMUS (1,847) CYCLOPHOSPHAMIDE (1,597) MYCOPHENOLATE MOFETIL (1,566) PREDNISONE (1,525) DEXAMETHASONE (1,355) METHOTREXATE (1,317) METHYLPREDNISOLONE (1,278) RITUXIMAB (1,188) PREDNISOLONE (1,154) CYCLOSPORINE (933)

Which OFATUMUMAB Alternatives Have Lower Multiple organ dysfunction syndrome Risk?

OFATUMUMAB vs OFLOXACIN OFATUMUMAB vs OLANZAPINE OFATUMUMAB vs OLANZAPINE\SAMIDORPHAN L-MALATE OFATUMUMAB vs OLAPARIB OFATUMUMAB vs OLARATUMAB

Related Pages

OFATUMUMAB Full Profile All Multiple organ dysfunction syndrome Reports All Drugs Causing Multiple organ dysfunction syndrome OFATUMUMAB Demographics